RXI-209

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameRXI-209
Drug Alias NamesiRNA therapeutics for liver fibrosis(RXi Pharmaceuticals)RXI-209
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLiver Cirrhosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPhio Pharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPhio Pharmaceuticals Corp
Active IndicationsN/A
Inactive IndicationsLiver Cirrhosis

Other Information

ATC CodeN/A
Related LinksN/A